Free Trial
NASDAQ:VIR

Vir Biotechnology (VIR) Stock Price, News & Analysis

Vir Biotechnology logo
$5.93 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$6.04 +0.11 (+1.85%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vir Biotechnology Stock (NASDAQ:VIR)

Key Stats

Today's Range
$5.88
$6.23
50-Day Range
$4.50
$6.16
52-Week Range
$4.32
$14.45
Volume
2.06 million shs
Average Volume
1.37 million shs
Market Capitalization
$819.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.86
Consensus Rating
Moderate Buy

Company Overview

Vir Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

VIR MarketRank™: 

Vir Biotechnology scored higher than 65% of companies evaluated by MarketBeat, and ranked 394th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Vir Biotechnology has only been the subject of 2 research reports in the past 90 days.

  • Read more about Vir Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Vir Biotechnology are expected to grow in the coming year, from ($3.92) to ($3.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vir Biotechnology is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vir Biotechnology is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vir Biotechnology has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Vir Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    12.76% of the float of Vir Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Vir Biotechnology has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Vir Biotechnology has recently decreased by 1.30%, indicating that investor sentiment is improving.
  • Dividend Yield

    Vir Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Vir Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.76% of the float of Vir Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Vir Biotechnology has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in Vir Biotechnology has recently decreased by 1.30%, indicating that investor sentiment is improving.
  • News Sentiment

    Vir Biotechnology has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $128,360.00 in company stock.

  • Percentage Held by Insiders

    16.00% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vir Biotechnology's insider trading history.
Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

VIR Stock News Headlines

AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
See More Headlines

VIR Stock Analysis - Frequently Asked Questions

Vir Biotechnology's stock was trading at $7.34 at the beginning of 2025. Since then, VIR stock has decreased by 19.2% and is now trading at $5.93.

Vir Biotechnology, Inc. (NASDAQ:VIR) released its earnings results on Wednesday, May, 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by $0.05. Vir Biotechnology's revenue was down 94.6% on a year-over-year basis.
Read the conference call transcript
.

Vir Biotechnology (VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

Top institutional investors of Vir Biotechnology include Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Backer Marianne De, George A Scangos, Phillip Pang, Howard Horn, Ann M Hanly, Steven J Rice, Sung Lee, Verneuil Vanina De, Brent Sabatini, Janet Napolitano, Saira Ramasastry and Charles Elliott Sigal.
View institutional ownership trends
.

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V).

Company Calendar

Last Earnings
5/07/2025
Today
7/10/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VIR
CIK
1706431
Fax
N/A
Employees
580
Year Founded
N/A

Price Target and Rating

High Price Target
$110.00
Low Price Target
$14.00
Potential Upside/Downside
+452.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$521.96 million
Net Margins
-2,769.04%
Pretax Margin
-2,775.77%
Return on Equity
-47.46%
Return on Assets
-39.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.79
Quick Ratio
6.79

Sales & Book Value

Annual Sales
$14.30 million
Price / Sales
57.44
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.35 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
138,238,000
Free Float
116,120,000
Market Cap
$821.55 million
Optionable
Optionable
Beta
1.22
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:VIR) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners